Neurocysticercosis Treatment & Management
- Author: Mohammed J Zafar, MD, FAAN; Chief Editor: Karen L Roos, MD more...
Approach Considerations
Treatment of neurocysticercosis depends upon the viability of the cyst and its complications.[12] Management includes symptomatic treatment as well as treatment directed against the parasite.[13]
Dead Parasite
If the parasite is dead, the treatment is directed primarily against the symptoms (eg, anticonvulsants for management of seizures). Monotherapy is usually sufficient. Duration of the treatment remains undefined, and depends neither on the type of seizure at presentation nor on other risk factors for recurrence, such as age at onset and number of seizures before diagnosis. Calcification remains an epileptogenic focus. Treating patients with viable cysts with a course of anticysticercal drugs in order to achieve better control of seizures is common practice.
Viable or Active Parasite
If the parasite is viable or active and the patient has vasculitis, arachnoiditis, or encephalitis, a course of steroids or immunosuppressants is recommended before the use of anticysticercal drugs. Antiparasitic treatment[14] with albendazole is also useful in cysticercosis of the racemose type.
If only parenchymal, subarachnoid, or spinal cysts are present without the complications mentioned previously (eg, chronic epilepsy, headaches, neurologic deficits related to strokes, and hydrocephalus), anticysticercal treatment can be considered, with the concomitant use of steroids, even in patients with massive brain infection. Reports indicate that multiple trials with anticysticercal treatment may be required for giant subarachnoid cysts.
A double-blind, placebo-controlled study showed that in patients with seizures due to viable parenchymal cysts, antiparasitic therapy decreases the burden of parasites and is safe and effective, at least in reducing the number of seizures with generalization.[15]
Surgical Intervention
In the presence of hydrocephalus due to an intraventricular cyst, placement of a ventricular shunt is recommended, followed by surgical extirpation of the cyst and subsequent medical treatment.[16]
In cases of multiple cysts in the subarachnoid space (ie, the racemose form), surgical extirpation, on an urgent basis, is recommended. If the obstruction is due to arachnoiditis, placement of a ventricular shunt should be followed by administration of steroids and subsequent medical therapy.
Because of frequent shunt dysfunctions due to entry of inflammatory tissue as well as parasitic debris inside the ventricular cavities, Sotelo designed a device that functions at a constant flow without the valvular mechanism of Pudenz-type shunts.
Surgical treatment in the particular case of medically refractory epilepsy due to a single lesion has been reported. Evaluation in an epilepsy center is indicated.
Neuroendoscopy is a tool with great potential for use in the management of ventricular cysticercosis.
Most patients with ocular or spinal lesions require surgical management.[17]
Long-Term Monitoring
Intracerebral cysticercotic lesions can cause epilepsy in the future. Administration of antiepileptic medication is the same as in any other epileptic syndrome.
Follow-up imaging study is recommended after 2-3 months following treatment, especially in cases in which anticysticercal medications are used as a diagnostic tool. The use of imaging will guide the requirement of future trials of anticysticercal medication in cases of subarachnoid cysticercosis.
Gubbay AD, Brophy BP, Henley S, Sage M. Neurocysticercosis. J Clin Neurosci. Apr 1998;5(2):203-7. [Medline].
Sinha S, Sharma BS. Neurocysticercosis: a review of current status and management. J Clin Neurosci. Jul 2009;16(7):867-76. [Medline].
Del Brutto OH, Garcia E, Talamas O, Sotelo J. Sex-related severity of inflammation in parenchymal brain cysticercosis. Arch Intern Med. Mar 1988;148(3):544-6. [Medline].
Gaffo AL, Guillen-Pinto D, Campos-Olazabal P, Burneo JG. [Cysticercosis as the main cause of partial seizures in children in Peru]. Rev Neurol. Nov 16-30 2004;39(10):924-6. [Medline].
Bickerstaff ER, Cloake PC, Hughes B, Smith WT. The racemose form of cerebral cysticercosis. Brain. Mar 1952;75(1):1-18. [Medline].
Del Brutto OH, Santibanez R, Noboa CA, Aguirre R, Diaz E, Alarcon TA. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology. Feb 1992;42(2):389-92. [Medline].
Chaoshuang L, Zhixin Z, Xiaohong W, Zhanlian H, Zhiliang G. Clinical analysis of 52 cases of neurocysticercosis. Trop Doct. Jul 2008;38(3):192-4. [Medline].
Barinagarrementeria F, Del Brutto OH. Lacunar syndrome due to neurocysticercosis. Arch Neurol. Apr 1989;46(4):415-7. [Medline].
Barinagarrementeria F, Cantu C. Neurocysticercosis as a cause of stroke. Stroke. Aug 1992;23(8):1180-1. [Medline].
Tian XJ, Li JY, Huang Y, Xue YP. Preliminary analysis of cerebrospinal fluid proteome in patients with neurocysticercosis. Chin Med J (Engl). May 5 2009;122(9):1003-8. [Medline].
Garcia HH, Martinez SM, eds. Taenia solium Taeniasis/Cysticercosis. 2nd ed. Lima, Peru: Editorial Universo; 1999.
Odermatt P, Preux PM, Druet-Cabanac M. Treatment of neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry. Sep 2008;79(9):978. [Medline].
Garg RK. Treatment of neurocysticercosis: is it beneficial?. Expert Rev Anti Infect Ther. Aug 2008;6(4):435-40. [Medline].
Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. Jan 15 2004;350(3):249-58. [Medline].
White AC Jr. New developments in the management of neurocysticercosis. J Infect Dis. May 1 2009;199(9):1261-2. [Medline].
Rangel-Castilla L, Serpa JA, Gopinath SP, Graviss EA, Diaz-Marchan P, White AC Jr. Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg. Mar 2009;80(3):373-8. [Medline].
White AC Jr, Weller PF. Cestodes. In: Kasper DL, Braunwald E, Hauser S, et al, eds. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill; 2004:Chapter 204.
Garg RK. Medical management of neurocysticercosis. Neurol India. Dec 2001;49(4):329-37. [Medline].
Sotelo J, Escobedo F, Penagos P. Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial. Arch Neurol. May 1988;45(5):532-4. [Medline].
Proano JV, Madrazo I, Avelar F, Lopez-Felix B, Diaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med. Sep 20 2001;345(12):879-85. [Medline].
Bittencourt PR, Gracia CM, Martins R, Fernandes AG, Diekmann HW, Jung W. Phenytoin and carbamazepine decreased oral bioavailability of praziquantel. Neurology. Mar 1992;42(3 Pt 1):492-6. [Medline].
Print
